Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Sino Biopharmaceutical (SBMFF) generated about CNY 31.8 billion in revenue and CNY 5.3 billion in net income (a 16.7% net margin) over the trailing twelve months, growing at roughly 4.3% a year. Figures are from SEC filings; this is analysis, not investment advice.
Sino Biopharmaceutical generated about CNY 31.8 billion in revenue over the trailing twelve months. Revenue has grown at roughly 4.3% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Yes, Sino Biopharmaceutical reported about CNY 5.3 billion in net income over the trailing twelve months, a net profit margin of roughly 16.7%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Sino Biopharmaceutical runs a gross margin of about 82.1%, an operating margin of about 21.7%, a net margin of about 16.7%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
Sino Biopharmaceutical's revenue has compounded at roughly 4.3% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside SBMFF's margins and free cash flow. This is analysis from SEC filings, not investment advice.